Biogen (BIIB) Receives Media Sentiment Rating of 0.27

Media headlines about Biogen (NASDAQ:BIIB) have been trending positive recently, according to Accern. The research group identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Biogen earned a news impact score of 0.27 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 45.7303444829009 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

Here are some of the news headlines that may have impacted Accern Sentiment Analysis’s analysis:

Shares of Biogen (NASDAQ BIIB) traded down 0.13% on Thursday, hitting $323.64. The stock had a trading volume of 1,136,440 shares. The stock has a market cap of $68.43 billion, a PE ratio of 21.24 and a beta of 0.77. The company has a 50 day moving average price of $297.83 and a 200-day moving average price of $278.11. Biogen has a 12 month low of $244.28 and a 12 month high of $330.00.

Biogen (NASDAQ:BIIB) last posted its earnings results on Tuesday, July 25th. The biotechnology company reported $5.04 earnings per share for the quarter, topping analysts’ consensus estimates of $4.36 by $0.68. Biogen had a net margin of 28.10% and a return on equity of 37.42%. The firm had revenue of $3.08 billion for the quarter, compared to the consensus estimate of $2.81 billion. During the same period in the previous year, the firm posted $5.21 EPS. The business’s quarterly revenue was up 6.4% on a year-over-year basis. On average, equities research analysts anticipate that Biogen will post $21.48 earnings per share for the current year.

BIIB has been the topic of several research analyst reports. Vetr downgraded Biogen from a “strong-buy” rating to a “buy” rating and set a $319.53 price objective on the stock. in a research note on Tuesday, August 29th. ValuEngine upgraded Biogen from a “hold” rating to a “buy” rating in a research report on Thursday, June 22nd. Mizuho dropped their target price on Biogen from $290.00 to $274.00 and set a “neutral” rating on the stock in a research report on Wednesday, May 31st. Cowen and Company restated an “outperform” rating and set a $271.00 target price on shares of Biogen in a research report on Monday, July 3rd. Finally, William Blair restated an “outperform” rating on shares of Biogen in a research report on Monday, June 26th. Thirteen equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have assigned a strong buy rating to the company. Biogen currently has a consensus rating of “Buy” and a consensus price target of $333.87.

COPYRIGHT VIOLATION NOTICE: “Biogen (BIIB) Receives Media Sentiment Rating of 0.27” was first posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be viewed at https://www.chaffeybreeze.com/2017/09/14/biogen-biib-receives-media-sentiment-rating-of-0-27.html.

In other news, EVP Susan H. Alexander sold 7,758 shares of the business’s stock in a transaction dated Wednesday, July 19th. The shares were sold at an average price of $285.00, for a total value of $2,211,030.00. Following the sale, the executive vice president now directly owns 27,232 shares in the company, valued at approximately $7,761,120. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Susan H. Alexander sold 4,974 shares of the business’s stock in a transaction dated Tuesday, July 25th. The stock was sold at an average price of $290.01, for a total transaction of $1,442,509.74. Following the completion of the sale, the executive vice president now owns 22,258 shares in the company, valued at $6,455,042.58. The disclosure for this sale can be found here. Insiders own 0.32% of the company’s stock.

Biogen Company Profile

Biogen Inc is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).

Insider Buying and Selling by Quarter for Biogen (NASDAQ:BIIB)

Receive News & Ratings for Biogen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply